Visa to buy BioCatch in a $2.4B deal aimed at fighting AI-fueled fraud

Visa is moving to deepen its fraud-fighting capabilities through a planned acquisition of BioCatch, an Israeli company that focuses on identifying suspicious behavior in digital transactions. The deal is reported to be valued at $2.4 billion, positioning Visa to add additional technology to help protect card payments from an evolving wave of fraud activity.

The planned purchase is framed as a response to fraud that increasingly leverages artificial intelligence, which can make scams more scalable and harder for traditional controls to detect. In its announcement as reported by Payments Dive and Yahoo Finance, Visa described the acquisition as part of a broader effort to strengthen defenses as adversaries adapt.

BioCatch is known in the fraud-prevention market for using behavioral and risk indicates to flag activity that looks abnormal or inconsistent with how a legitimate user typically behaves. For Visa, the appeal of that approach is that it can complement rule-based systems by bringing in patterns that may be harder to replicate across sessions, devices, or accounts.

Visa’s investment also underscores how card networks and issuers are rebalancing fraud strategies. As attackers refine their tactics, payment providers are increasingly looking to firms that can detect risky activity in real time and reduce false positives that can disrupt legitimate customer transactions.

While the reported $2.4 billion price tag indicates the importance Visa is assigning to the technology, Visa did not, in the reporting referenced here, provide additional specifics such as expected deal timing, funding details, or whether BioCatch would be integrated into a particular Visa risk or authentication product line.

For context, Visa operates in a payments ecosystem where multiple parties share responsibility for security and risk management, including card issuers, merchants, and Visa’s own network and risk services. In that environment, acquisitions are often used to broaden the set of detection indicates available to participants and to reduce the time it takes to deploy new capabilities.

Key details that investors and customers typically look for in deals like this were not included in the available reporting, including the expected closing conditions, any regulatory or antitrust milestones, and whether Visa intends to continue funding or expanding specific BioCatch platforms post-acquisition.

What to watch next is whether Visa and BioCatch will publish more comprehensive terms, including the acquisition timetable and how the companies plan to combine product capabilities for customers. Additional disclosures on the specific fraud risks targeted by the acquisition would also help clarify whether the focus is on specific channels, such as online account takeovers, payment authentication events, or broader transaction-risk scoring.